{
    "nct_id": "NCT05384626",
    "official_title": "A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)",
    "inclusion_criteria": "1. Age ≥18 years, Phase 2 Cohort 2f only: Age ≥12 years and weighing >40 kg.\n2. Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation.\n3. Phase 2\n\n   1. Phase 2 Cohorts except 2f: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement\n   2. Phase 2 Cohort 2f: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation detected by certified assay.\n4. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1 Phase 2: Must have measurable disease according to RECIST 1.1\n5. Adequate organ function and bone marrow reserve\n\nExclusion criteria:\n\n1. Patient's cancer has a known oncogenic driver alteration other than ALK.\n2. Known allergy/hypersensitivity to excipients of NVL-655.\n3. Major surgery within 4 weeks of the study entry\n4. Ongoing or anticancer therapy\n5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}